Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years

Björn Engelbrekt Wahlin1,2 | Ninja Övergaard3 | Stefan Peterson4 | Evangelos Digkas5 | Ingrid Glimelius3 | Ingemar Lagerlöf3,6 | Ann-Sofie Johansson7 | Marzia Palma2 | Lotta Hansson2 | Johan Linderoth8 | Christina Goldkuhl9 | Daniel Molin3

1 Division of Haematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
2 Haematology unit, Karolinska University Hospital, Stockholm, Sweden
3 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
4 Regional Cancer Center South, Lund, Sweden
5 Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden
6 Department of Haematology, University Hospital of Linköping, Linköping, Sweden
7 Department of Oncology, Umeå University, Umeå, Sweden
8 Department of Oncology, Lund University, Lund, Sweden
9 Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Correspondence
Ninja Övergaard, Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Akademiska sjukhuset, S-75185 Uppsala, Sweden.
Email: ninja.overegaard@igp.uu.se

Abstract
Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were >60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients > 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61–70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients > 60 years (p = 0.027), for whom ABVD seems superior to CHOP.

Keywords
classical Hodgkin lymphoma, older patients, population-based, survival, treatment
Younger patients with classical Hodgkin lymphoma (cHL) generally have a favourable prognosis, and in patients ≤ 60 years, recent debates on therapy for advanced-stage cHL have largely revolved around ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) versus BEACOPP-esc (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).[1–4]

In the older patient, the prognosis is much poorer,[5–8] men have a worse prognosis than women in all ages [9], and a gold standard for treatment of patients > 60 years is yet to be established.

The CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen has, during 2000–2017, been used to treat elderly cHL patients > 70 years in Sweden. In a small Norwegian retrospective single centre study, the CHOP regimen showed promising overall survival (OS) and progression-free survival at 3 years of 79% and 76%, respectively.[10] ABVD is a standard treatment for younger patients and has also been tried in older patients. When used to treat elderly patients ABVD has a higher incidence of toxicity, in particular bleomycin-related pulmonary toxicity.[11] More intensive chemotherapy combinations like BEACOPP have been associated with unacceptable toxicity and are generally not recommended for patients > 60 years.[12]

With the introduction of brentuximab vedotin and immune checkpoint inhibitors in relapsed patients, the option of moving those treatments into first-line has emerged. The B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone) regimen is such an attempt.[13]

Older patients and patients with severe comorbidities and social problems are often excluded from clinical trials.[14] Previous population-based studies of adult cHL patients have been performed in Sweden [15–17] and elsewhere.[18–20] In the study performed by Bjorkholm, patients diagnosed between the years 1973 and 2014 demonstrated improved relative survival (RS) over time in all patient subgroups, including the elderly.[17] However, the outcome for the older patient is still dismal, especially in men, with limited difference in trends over time, and it was demonstrated that greater attention to the development of therapies for the older cHL patients is needed. Population-based studies provide a true, real-world, picture of treatment outcome and survival but continuous evaluations are needed, following changes in treatment standards, to identify unmet medical needs.

In the present study, we have analysed the difference in treatment outcome and patient characteristics with focus on the older patient group > 60 years.

2 | METHODS

2.1 | Swedish registries

Every clinician and pathologist/cytologist in Sweden is obliged by law to report each occurrence of cancer to the Swedish Cancer Registry (SCR).[21] The SCR includes diagnosis, gender, date of birth, date of diagnosis and the hospital where the diagnosis was made. The SCR and its diagnostic classification were introduced in 1958. By the 1990s, the Swedish Lymphoma Group commissioned the Swedish Lymphoma Registry (SLR), and it was launched nationwide on 1 January 2000.[22, 23] According to yearly reports, the coverage in SLR compared to the SCR has been 95%–97% since its initiation.[22] The SLR has been validated, showing a 95% agreement between the diagnosis reported to the SLR and the local patient files.[22] In June 2007, additional prognostic factors were added to the report form, allowing the calculation of the International Prognostic Score (IPS).[9] For residents in Sweden, date of death is centrally registered in the Causes of Death Registry,[24, 25] from which survival data were obtained.

2.2 | Patients

All Swedish patients with newly diagnosed cHL and registered in the SLR from 1st January 2000 to 31st December 2014 were included in the analysis. Patients were not excluded due to comorbidities. All patients were observed from date of diagnosis until death, emigration or end of follow-up (28th February 2015). Information on first-line therapy, age, gender, WHO performance status, Ann Arbor stage, lactate dehydrogenase, B symptoms and IPS factors were obtained from the SLR. Sweden is divided into six Healthcare Regions, each with a population of 0.9–2.3 million people and a tertiary lymphoma centre, but cHL patients are treated also in smaller hospitals in every Region. In general, cHL patients are treated according to national guidelines,[26] which were first introduced in 1985 and since then regularly updated. This study was approved by the Ethics Committee, Stockholm.

2.3 | An overview of treatment for HL in Sweden during 2000–2014

2.3.1 | Patients ≤ 60 years

Patients with stage I-IIA and no risk factor (bulky disease, erythrocyte sedimentation rate > 50 mm or more than two involved sites) were given two courses of ABVD and in the beginning of the period followed by radiotherapy (RT) to 30 Gy or, in the latter part of the period, RT to 20 Gy in 2 Gy fractions, while those with any risk factor were treated with four ABVD followed by RT to 30 Gy or 29.75 Gy in 1.75 Gy fractions. Stage IB patients were treated with four ABVD plus RT to 30/29.75 Gy or as advanced-stage disease (IIB-IV). In the beginning
of the studied period, RT was given as limited field RT (i.e., modified involved field) which gradually was replaced by involved site/node RT as radiological imaging techniques were refined. Patients with stage IIB-IV disease, ≤60 years and IPS ≤ 2 were recommended 6–8 courses of ABVD [9] while those ≤ 60 and IPS > 2 were recommended six BEACOPPesc or eight BEACOPP-14. In January 2011, when the RATHL trial [3] was launched in Sweden, all centers adopted its algorithm: six courses of ABVD with interim 18F-fluorodeoxyglucose-positron emission tomography/computer tomography (FDG-PET/CT) after two courses, and those who did not show complete metabolic remission switched to BEACOPP-14. This became the standard for patients with IPS ≤ 2 for the remainder of the study period (alongside six BEACOPPesc or eight BEACOPP-14 for IPS > 2).

### 2.3.2 Patients 61–70 years

Patients aged 61–70 with stage I-IIA disease received treatment according to the same guidelines as patients ≤ 60 years. For stage IIB-IV, patients aged 61–70 years were recommended six-eight courses of ABVD.

### 2.3.3 Patients ≥ 71 years

Stage I-IIA without risk factors was treated with two cycles of CHOP followed by 30 Gy LF-RT/IMRT/ISRRT in 2 Gy fractions, whereas stage I-IIA with any risk factor received four cycles of CHOP and 30 Gy RT. Stage IB was either given four cycles of CHOP and 30 Gy RT or six cycles of CHOP. Advanced stages were recommended six cycles of CHOP as standard treatment; however, some centers also used ABVD in patients > 70.

### 2.4 Survival analysis

Survival of patients diagnosed with cHL was estimated using univariable Kaplan-Meier and multivariable Cox OS analysis [27, 28] as well as univariable and multivariable RS analysis.[29, 30] From Swedish population life tables stratified by sex, age and calendar period, expected survival was assessed using the Ederer II method.[31] RS ratios (RSR) were estimated for patients in the three calendar periods and in four age groups (≤45, 46–60, 61–70 and ≥71 years). Multivariable models for excess mortality were calculated using the expectation-maximization algorithm, employing a smoothed baseline excess hazard, yielding excess-mortality rate-ratios as estimates.[32] The excess-mortality rate-ratio denotes excess mortality (the difference between observed and expected mortality in the general population). The RS calculations were performed using R software (Maja Pohar Perme [2013]: relsurv, R package version 2.0-4 [http://CRAN.R-project.org/package=relsurv]); all other calculations with Stata version 9.2 (StatCorp, College Station, TX, USA).

### 3 RESULTS

A total of 2345 cHL patients (1257 men and 1088 women) were diagnosed in Sweden from year 2000 through 2014 (Table 1). Of all the patients, 294 were 61–70 years and 397 were ≥71 (Table 2). The median age at diagnosis was 42 years and increased over time (p = 0.010). The proportion of nodular sclerosis cases decreased (p = 0.003). There were no changes in WHO performance status or B symptoms over time. The median follow-up time was 6.7 years (2000–2004, 12.8 years; 2005–2009, 7.5 years; 2010–2014, 2.8 years). Complete information on treatment was available in 1466 patients (417 patients ≥ 61 years). The IPS score, available from June 2007, predicted OS (p < 0.00005); however, because of its late adoption into the registry, IPS could not be used in multivariable analyses.

#### 3.1 Survival analysis

OS at 3 and 5 years was 83% (95% confidence interval [CI], 81%–84%) and 79% (95% CI, 77%–81%), respectively. OS at 3 years according to age, stage and sex is shown in Table 3. Survival did not change over time, neither in limited (p = 0.67) nor advanced-stage (p = 0.76) disease (Figure S1B). In patients 61–70 years, 3- and 5-year OS was 71% and 64% and in patients ≥ 71 years, 42% and 33%.

In patients ≥ 61 years, OS was better in those diagnosed between 2010 and 2014 than in those diagnosed between 2000 and 2009 (p = 0.027); this was not seen in patients ≤ 60 years (p = 0.49; Figure 1A). The improvement in patients ≥ 61 was due to better OS in advanced-stage disease (p = 0.011; Figures 1B-C), and in women (p = 0.005; Figures 1D and 1E, Table 4), but not in patients with limited-stage disease (p = 0.34). There were no survival differences between the Healthcare Regions.

The women’s IPS scores did not change over time, and 26% were high-risk (IPS > 2) both 2000–2009 and 2010–2014. Furthermore, there was no change in their performance status, histology or the incidence of B symptoms (data not shown). The fraction of stage IV cases increased in the last calendar period (from 18% to 25%; p = 0.00005); this was seen over all categories: female (from 15% to 22%; p = 0.003), male (from 21% to 28%; p = 0.006), ≤60 years old (from 16% to 22%; p = 0.001) and >60 years old patients (from 23% to 31%; p = 0.044).

#### 3.2 Chemotherapy regimens

Chemotherapy regimens by age, sex and calendar periods are presented in Table 5. In multivariable analysis of patients > 60 years, CHOP compared to ABVD was an independent adverse factor for OS (p = 0.039; Table 4, see also Figure 1F). When repeating the multivariable analysis only in patients aged 61–70 years, CHOP was still inferior to ABVD (HR, 1.72; p = 0.039). Only nine patients ≥ 71 years had received ABVD, why statistical significance could not be achieved (p = 0.097).
| Characteristic               | 2000–2004 (N = 731) | Period | 2005–2009 (N = 800) | 2010–2014 (N = 814) | Total (N = 2345) | Univariable analysis with respect to overall survival HR (95% CI) |
|-----------------------------|---------------------|--------|---------------------|---------------------|------------------|---------------------------------------------------------------|
| **Age, years**              |                     |        |                     |                     |                  |                                                               |
| Median (range)              | 38 (16–93)          | 43 (16–99) | 45 (16–94)          | 42 (16–99)          | 1242             | 53.2                                                          |
| 16–45                       | 408                 | 55.8   | 420                 | 53.1                | 1242             | 53.2                                                          |
| 46–60                       | 126                 | 17.2   | 131                 | 16.6                | 401              | 17.2                                                          |
| 61–70                       | 78                  | 10.7   | 108                 | 13.7                | 294              | 12.6                                                          |
| 71–99                       | 119                 | 16.3   | 132                 | 16.7                | 397              | 17.0                                                          |
| **Histology subtype**       |                     |        |                     |                     |                  |                                                               |
| NS                          | 460                 | 62.9   | 478                 | 59.8                | 1390             | 59.3                                                          |
| Not NS                      | 167                 | 22.8   | 203                 | 25.4                | 557              | 23.8                                                          |
| Unspecified                 | 104                 | 14.2   | 119                 | 14.9                | 398              | 17.0                                                          |
| **Sex**                     |                     |        |                     |                     |                  |                                                               |
| Female                      | 355                 | 48.6   | 362                 | 45.3                | 1088             | 46.4                                                          |
| Male                        | 376                 | 51.4   | 438                 | 54.8                | 1257             | 53.6                                                          |
| **Ann Arbor stage**         |                     |        |                     |                     |                  |                                                               |
| I                           | 121                 | 16.8   | 110                 | 14.0                | 329              | 14.3                                                          |
| II                          | 326                 | 45.3   | 332                 | 42.4                | 996              | 43.4                                                          |
| III                         | 159                 | 22.1   | 182                 | 23.2                | 498              | 21.7                                                          |
| IV                          | 113                 | 15.7   | 159                 | 20.3                | 473              | 20.6                                                          |
| **B symptoms**              |                     |        |                     |                     |                  |                                                               |
| Absent                      | 384                 | 54.3   | 408                 | 52.0                | 1224             | 53.3                                                          |
| Present                     | 323                 | 45.7   | 377                 | 48.0                | 1072             | 46.7                                                          |

(Continues)
| Characteristic | 2000–2004 (N = 731) | 2005–2009 (N = 800) | 2010–2014 (N = 814) | Total (N = 2345) | Univariable analysis with respect to overall survival HR (95% CI) |
|----------------|----------------------|----------------------|----------------------|------------------|---------------------------------------------------------------|
|                | Number | %      | Number | %      | Number | %      | Number | %      |                    |
| **Advanced stage disease (IIB, III, and IV)** | 393    | 55.0   | 467    | 60.0   | 474    | 59.7   | 1334   | 58.3   | 2.24 (1.85–2.71)   |
| **WHO performance** |         |        |         |        |         |        |         |        |                    |
| 0              | 454    | 62.1   | 529    | 66.1   | 528    | 64.9   | 1511   | 64.4   | 1                  |
| 1              | 189    | 25.9   | 179    | 22.4   | 203    | 24.9   | 571    | 24.3   | 3.65 (3.00–4.44)   |
| ≥2             | 88     | 12.0   | 92     | 11.5   | 83     | 10.2   | 263    | 11.2   | 9.24 (7.49–11.39)  |
| **Other IPS factors** |         |        |         |        |         |        |         |        |                    |
| Age over 45 years | 323    | 44.2   | 371    | 46.9   | 398    | 49.0   | 1092   | 46.8   | 8.26 (6.60–10.33)  |
| Hb < 10.5 g/dl | -      | -      | 53     | 17.3   | 133    | 17.3   | 186    | 17.3   | 3.24 (2.42–4.35)   |
| Albumin <40 g/l | -      | -      | 193    | 65.4   | 491    | 66.6   | 685    | 66.3   | 3.46 (2.29–5.25)   |
| WBC > 15/nl    | -      | -      | 32     | 10.5   | 67     | 8.7    | 99     | 9.2    | 1.26 (0.81–1.96)   |
| B-cells < 8% or <0.6/nl | -      | -      | 40     | 14.3   | 87     | 12.1   | 127    | 12.7   | 3.02 (2.15–4.25)   |
| **IPS**         |         |        |         |        |         |        |         |        |                    |
| 0 to 2         | -      | -      | 169    | 52.8   | 425    | 56.9   | 594    | 53.9   | 1                  |
| 3 to 7         | -      | -      | 151    | 47.2   | 322    | 43.1   | 508    | 46.1   | 6.36 (4.53–8.91)   |
**FIGURE 1** Overall survival. By (A) calendar period and age for all patients, (B) calendar period and age in limited (I-IIA) stages, (C) calendar period and age in advanced (IIB-IV) stages, (D) calendar period and age in men with advanced stages, (E) calendar period in women with advanced stages, (F) CHOP or ABVD in patients ≥ 61 years of age, (G) BEACOPP or ABVD in patients ≤ 60 years with advanced stages
**TABLE 2** Clinical characteristics – patients > 60 years

| Characteristics          | ABVD | CHOP | Other | None | Total |
|--------------------------|------|------|-------|------|-------|
| **Age, years**           |      |      |       |      |       |
| 61–70                    | 112  | 58   | 51    | 26   | 294   |
| 71–99                    | 9    | 4    | 145   | 65   | 397   |
| **Sex**                  |      |      |       |      |       |
| Female                   | 42   | 24   | 91    | 52   | 304   |
| Male                     | 79   | 33   | 105   | 43   | 387   |
| **Histology, subtype**   |      |      |       |      |       |
| NS                       | 51   | 33   | 70    | 45   | 257   |
| Non-NS                   | 43   | 28   | 78    | 50   | 258   |
| Unspecified              | 27   | 25   | 48    | 45   | 176   |
| **Ann Arbor stage**      |      |      |       |      |       |
| I                        | 29   | 48   | 36    | 36   | 121   |
| II                       | 37   | 34   | 51    | 51   | 173   |
| III                      | 26   | 23   | 52    | 52   | 188   |
| IV                       | 26   | 24   | 47    | 47   | 167   |
| Missing                  | 3    | 14   | 32    | 32   | 44    |
| **B-symptoms**           |      |      |       |      |       |
| No                       | 64   | 38   | 76    | 45   | 316   |
| Yes                      | 57   | 24   | 117   | 49   | 353   |
| Missing                  | 0    | 0    | 3     | 30   | 22    |
| **WHO performance**      |      |      |       |      |       |
| 0                        | 78   | 45   | 70    | 40   | 278   |
| 1                        | 35   | 23   | 87    | 58   | 238   |
| >2                       | 7    | 8    | 37    | 41   | 161   |
| Missing                  | 1    | 20   | 2     | 40   | 14    |
| **IPS**                  |      |      |       |      |       |
| 0–2                      | 27   | 41   | 28    | 42   | 105   |
| 3–7                      | 47   | 25   | 90    | 49   | 264   |
| Radiation therapy        |      |      |       |      |       |
| Yes                      | 54   | 26   | 95    | 45   | 223   |
| No                       | 67   | 33   | 101   | 49   | 215   |
| Missing                  | na   | na   | na    | na   | 253   |

Patients ≤ 60 years with advanced-stage disease treated with BEACOPP and ABVD showed identical OS in univariable (Figure 1G) and multivariable analysis (adjusted for the same covariates as in Table 3; \( p = 0.51 \)). In patients with complete information and IPS-score > 2, there was a trend \( (p = 0.33) \) for better OS with BEACOPP. The patients treated with BEACOPP were older than those treated with ABVD (median age, 33 vs. 30 years; \( p = 0.012 \)).

### 3.3 RS

RS was stable between the calendar periods (Figures 2 and S2), except for an improvement in elderly women with advanced stage disease diagnosed between 2010 and 2014 (Figure 2B; Table 1). CHOP seems inferior to ABVD in the older patient group, while BEACOPP was equal to ABVD in younger patients with advanced-stage disease (Figure 2), also after adjustment for clinical factors (Table 4).

### 4 DISCUSSION

Using the SLR, we have performed a retrospective analysis of all 2345 patients registered with cHL in Sweden from 2000 through 2014, with focus on patients > 60 years. ABVD seems superior to CHOP for older patients, a finding that should be interpreted with caution even if it was significant in multivariable analysis due to the obvious risk of selection.
TABLE 3  Overall survival at 3 years

| Category | Overall survival, at 3 years | 2000–2009 | 95% CI | 2010–2014 | 95% CI |
|----------|-------------------------------|-----------|--------|-----------|--------|
| All patients |                               |           |        |           |        |
| ≤45      |                               | 97%       | 95%–98%| 96%       | 94%–98%|
| 46–60    |                               | 89%       | 85%–92%| 89%       | 81%–93%|
| 61–70    |                               | 68%       | 61%–74%| 79%       | 69%–86%|
| ≥71      |                               | 40%       | 34%–46%| 47%       | 37%–56%|
| Limited stages |                               |           |        |           |        |
| ≤45      |                               | 98%       | 96%–99%| 98%       | 94%–99%|
| 46–60    |                               | 97%       | 92%–99%| 91%       | 77%–97%|
| 61–70    |                               | 87%       | 77%–93%| 96%       | 76%–99%|
| ≥71      |                               | 63%       | 51%–72%| 71%       | 53%–83%|
| Advanced stages |                               |           |        |           |        |
| ≤45      |                               | 96%       | 94%–97%| 95%       | 90%–97%|
| 46–60    |                               | 83%       | 76%–88%| 87%       | 75%–93%|
| 61–70    |                               | 57%       | 47%–66%| 73%       | 60%–82%|
| ≥71      |                               | 34%       | 26%–41%| 44%       | 32%–55%|
| Advanced stages, men |                               |           |        |           |        |
| ≤45      |                               | 94%       | 90%–97%| 91%       | 83%–95%|
| 46–60    |                               | 83%       | 73%–89%| 87%       | 72%–94%|
| 61–70    |                               | 59%       | 46%–69%| 67%       | 51%–79%|
| ≥71      |                               | 39%       | 29%–49%| 36%       | 21%–51%|
| Advanced stages, women |                               |           |        |           |        |
| ≤45      |                               | 98%       | 94%–99%| 99%       | 93%–100%|
| 46–60    |                               | 83%       | 69%–91%| 87%       | 65%–96%|
| 61–70    |                               | 55%       | 39%–68%| 82%       | 61%–92%|
| ≥71      |                               | 25%       | 15%–37%| 54%       | 35%–69%|

TABLE 4  Multivariable models

| Subset | Factor | Overall survival | Relative survival |
|--------|--------|------------------|-------------------|
|        |        | HR    | 95% CI | RR    | 95% CI |
| Women > 60 years stage IIB-IV | WHO > 1 | 3.34  | 2.23–4.99 | 4.26  | 2.63–6.89 |
| (N = 174) | Age > 70 years | 2.11  | 1.37–3.25 | 1.61  | 0.97–2.65 |
|          | Period 2010–2014 | 0.53  | 0.33–0.86 | 0.49  | 0.28–0.87 |
| Patients > 60 years | WHO > 1 | 2.88  | 1.94–4.27 | 3.31  | 2.10–5.23 |
| (N = 304) | Age > 70 years | 1.40  | 0.95–2.07 | 1.16  | 0.71–1.90 |
|          | Stage IIB-IV | 2.37  | 1.52–3.70 | 3.39  | 1.57–7.28 |
|          | CHOP vs. ABVD | 1.80  | 1.14–2.85 | 2.30  | 1.24–4.28 |

Competing, non-significant factors: Histology, LDH, B symptoms (and, in the latter analysis, male sex).
Abbreviation: CI, confidence interval; HR, hazard ratio; RR, relative risk.

bias. Agreeing with previous reports,[10, 11, 15, 33] prognosis remains poor for patients > 60 years. This is due to their inability to tolerate BEACOPP [12] or ABVD,[11] higher co-morbidity [7] and differences in lymphoma biology (more mixed cellularity, Epstein-Barr virus positivity and infradiaphragmatic disease).[7] FDG-PET/CT was gradually introduced, and a stage migration was seen over time as increased number of patients presenting with stage IV disease in the last calendar period, also in the older patient group.

In Sweden, between 2000 and 2014 there was no improvement in survival except in patients > 60 years. Improved survival, especially...
### TABLE 5  Chemotherapy regimens according to subsets

| Subset                | All patients | Therapy | Age group | ≤45  | 46–60 | 61–70 | ≥71  | All ages |
|-----------------------|--------------|---------|-----------|-------|-------|-------|-------|----------|
| **Limited stages**    |              |         |           |       |       |       |       |          |
| 2000–2009 Men         |              |         |           |       |       |       |       |          |
| Advanced stages       | None         | 0%      | 0%        | 2%    | 13%   | 2%    | 2%    |          |
| Crown                | Reduced      | 3%      | 2%        | 9%    | 17%   | 6%    |       |          |
|                     | CHOP         | 0%      | 2%        | 26%   | 65%   | 14%   |       |          |
|                     | ABVD         | 80%     | 77%       | 58%   | 4%    | 65%   |       |          |
|                     | BEACOPP      | 17%     | 18%       | 5%    | 1%    | 13%   |       |          |
| Advanced stages       | None         | 0%      | 1%        | 2%    | 18%   | 2%    | 2%    |          |
| 2010–2014 Men         | Reduced      | 3%      | 4%        | 8%    | 7%    | 3%    | 13%   |          |
|                     | CHOP         | 0%      | 1%        | 8%    | 7%    | 3%    | 13%   |          |
|                     | ABVD         | 95%     | 97%       | 76%   | 7%    | 85%   |       |          |
|                     | BEACOPP      | 2%      | 0%        | 0%    | 0%    | 2%    |       |          |
| Limited stages       | None         | 0%      | 1%        | 2%    | 18%   | 2%    | 2%    |          |
| 2000–2009 Men         | Reduced      | 3%      | 4%        | 8%    | 21%   | 7%    | 21%   |          |
|                     | CHOP         | 0%      | 2%        | 33%   | 67%   | 17%   |       |          |
|                     | ABVD         | 68%     | 61%       | 50%   | 3%    | 52%   |       |          |
|                     | BEACOPP      | 29%     | 33%       | 7%    | 1%    | 22%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 2%    | 8%    | 2%    |       |          |
| 2010–2014 Men         | Reduced      | 4%      | 5%        | 9%    | 22%   | 8%    |       |          |
|                     | CHOP         | 68%     | 60%       | 41%   | 3%    | 52%   |       |          |
|                     | ABVD         | 0%      | 3%        | 43%   | 65%   | 17%   |       |          |
|                     | BEACOPP      | 29%     | 32%       | 7%    | 1%    | 22%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 4%    | 7%    | 2%    |       |          |
| 2010–2014 Men         | Reduced      | 1%      | 2%        | 6%    | 20%   | 6%    |       |          |
|                     | CHOP         | 0%      | 0%        | 18%   | 7%    | 18%   |       |          |
|                     | ABVD         | 69%     | 64%       | 64%   | 2%    | 53%   |       |          |
|                     | BEACOPP      | 30%     | 34%       | 8%    | 2%    | 21%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 0%    | 9%    | 2%    |       |          |
| 2000–2009 Women       | Reduced      | 5%      | 7%        | 12%   | 20%   | 9%    |       |          |
| Men                   | CHOP         | 0%      | 3%        | 38%   | 69%   | 18%   |       |          |
|                     | ABVD         | 62%     | 55%       | 42%   | 2%    | 47%   |       |          |
|                     | BEACOPP      | 34%     | 34%       | 8%    | 0%    | 25%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 3%    | 3%    | 1%    |       |          |
| 2010–2014 Men         | Reduced      | 1%      | 0%        | 7%    | 30%   | 7%    |       |          |
| Men                   | CHOP         | 0%      | 0%        | 13%   | 60%   | 13%   |       |          |
|                     | ABVD         | 65%     | 67%       | 67%   | 3%    | 55%   |       |          |
|                     | BEACOPP      | 33%     | 33%       | 10%   | 3%    | 24%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 0%    | 8%    | 1%    |       |          |
| 2000–2009 Women       | Reduced      | 2%      | 0%        | 4%    | 24%   | 6%    |       |          |
| Women                 | CHOP         | 0%      | 3%        | 54%   | 59%   | 16%   |       |          |
|                     | ABVD         | 75%     | 69%       | 38%   | 5%    | 58%   |       |          |
|                     | BEACOPP      | 23%     | 28%       | 4%    | 3%    | 19%   |       |          |
| Advanced stages       | None         | 0%      | 0%        | 5%    | 10%   | 3%    |       |          |
| 2010–2014 Women       | Reduced      | 0%      | 6%        | 5%    | 10%   | 4%    |       |          |
|                      | CHOP         | 0%      | 0%        | 25%   | 80%   | 23%   |       |          |
|                      | ABVD         | 73%     | 59%       | 60%   | 0%    | 52%   |       |          |
|                      | BEACOPP      | 27%     | 35%       | 5%    | 0%    | 18%   |       |          |
in elderly women, was seen in nationwide Swedish studies of patients diagnosed with follicular lymphoma (FL) and advanced nodular lymphocyte predominant HL [34, 35] during the same time period.

In Sweden, CHOP has been used for patients over 70 years of age since 2000, based on the results from a Norwegian study.[10] For those aged 60–70 years, ABVD was recommended. In our material, CHOP (compared with ABVD) was an independent adverse factor for OS in patients ≥ 61 years, when adjusted for available risk factors. Hence, ABVD is preferable for those fit to receive such treatment. Given that ABVD provides better outcome than CHOP and that bleomycin toxicity is a major problem in older patients receiving more than two cycles of ABVD,[11, 36] the option of excluding bleomycin is tempting. There are studies indicating that the omission of bleomycin has a relatively small impact on efficacy.[3, 37] AVD (doxorubicin, vinblastine, dacarbazine) can also be given with G-CSF (granulocyte colony-stimulating factor) support without the risk of lung injury. A study in which bleomycin was removed or reduced in 53 of 147 patients > 60 years, mainly due to lung toxicity, came to the same conclusion.[38] and in the Swedish national guidelines [26] AVD (doxorubicin, vincristine and dacarbazine) is recommended to patients > 70 years as first-line treatment since 2017. In Sweden AVD is also used to treat patients 61–70 years with co-morbidity, not fit for ABVD.

Other alternatives for treating the elderly are being explored, for example, in a co-operative phase II study between the German Hodgkin study group and the Nordic lymphoma group, where B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone) was used for those fit to receive combination chemotherapy. Patients not fit for combination chemotherapy were treated with brentuximab vedotin monotherapy.[13] Unfortunately, preliminary results have not reached a sufficient level to form a new standard.[39] This may in part be due to the CHOP backbone that brentuximab vedotin was combined with.

Younger patients with IPS 0–2 were treated with 6–8 ABVD, and those with IPS 3–7 received either 6–8 ABVD or BEACOPP-14/esc. In recent years, the ABVD treatment has been PET-guided, with escalation to BEACOPP-14/esc for PET-positive patients.

Currently, the German standard for advanced stage disease is 4–6 [4] courses of BEACOPPesc [2], and in multiple studies, survival has been superior for the BEACOPP-regimens.[2, 4, 40–45]

In a previous Swedish study of long-term survival after cHL, where data from patients treated between 1992 and 2009 (N = 1947, age 18–59 years) were analysed, the survival of relapse-free patients was similar to that of the general population, while the relapsed patients had an excess mortality 19 times higher compared to the relapse-free.[16]
In our material, patients ≤ 60 years with advanced-stage disease treated initially with BEACOPP-14/esc versus ABVD showed identical OS in univariable and multivariable analysis. These data indicate that a PET-guided ABVD approach is suitable for a proportion of the advanced-stage patients. However, the IPS score, available from June 2007, predicted OS (p < 0.00005), suggesting that a proportion of those with high-risk score might need a more aggressive approach from the start. Since BEACOPP was only given to high-risk patients, according to IPS, it could be argued that the identical OS might suggest that BEACOPP is beneficial for this group. For the patients > 60 years, no PET-guided approach is available due to the lack of any evidence-based escalation-regimen.

The strengths of our study are that it is population-based, consecutive and based on real-life data. No regional differences were seen in treatment or survival. One weakness is the bias in the selection of chemotherapy regimens used, especially for CHOP versus ABVD in older patients but also in ABVD versus BEACOPP-14/esc for the younger. Some patients starting with ABVD escalated to BEACOPP-14/esc due to positive PET/CT. Another weakness is the limited follow-up time for patients in the latest calendar period, reducing the possibility to distinguish toxicity form anti-lymphoma effect. Furthermore, the SLR lacks information on relapse, and cause of death; however, the RSR analysis abrogates that. Because the IPS was introduced only recently into the registry, a proper comparison between ABVD and BEACOPP-14/esc when indicated (≤60 years, advanced-stage and IPS > 2) could not be satisfactorily performed.

In conclusion, ABVD seems superior to CHOP for patients > 60 years who can tolerate this regimen and since the study period, the treatment of patients > 70 years and older frail patients, has been changed from CHOP to AVD in clinical routine in the Nordic countries. Outcome was not improved over time from 2000 to 2014, except in older patients, but further investigation and longer follow-up are needed to confirm this observation. The implementation of FDG-PET/CT coincided with a stage migration seen in real life as an increase in stage IV disease, also in the older patient group (Table 1).

ACKNOWLEDGEMENTS
The authors wish to thank the Swedish Lymphoma Group, the Swedish Hodgkin Lymphoma Group, the Swedish Lymphoma Registry and all persons reporting to this registry. Funded by grants from Cancerfonden, Svenska Sällskapet för Medicinsk Forskning (SSMF), Stockholm County Council (clinical postdoctoral appointment for BEW), Stiftelsen Onkologiska Kliniken i Uppsala Cancerforskningsfond and Lion’s Cancerforskningsfond vid Akademiska sjukhuset.

CONFLICT OF INTEREST
Daniel Molin has received honoraria from Roche, Merck, Bristol-Myers Squibb and Takeda. Björn Engelbrekt Wahlin has received research funding from Roche and Gilead, and he has been a consultant for Roche and Gilead. Lotta Hansson has received research grant support from Gilead and Janssen-Cilag and honoraria from Abbvie. Ingrid Glimelius has received honoraria from Janssen-Cilag. Marzia Palma has received research grant support from Beigene and Takeda. None of the other authors have any relevant conflict of interest to disclose.

AUTHOR CONTRIBUTIONS
Björn Engelbrekt Wahlin wrote the manuscript and interpreted the data together with Ninja Övergaard and Daniel Molin and performed the statistics together with Stefan Peterson. Stefan Peterson made statistical analyses, especially relative survival and participated in the writing of the manuscript. Evangelos Digkas and Ingrid Glimelius participated in the writing of the manuscript. Ingemar Lagerlöf, Ann-Sofie Johansson, Marzia Palma, Lotta Hansson, Johan Linderoth and Christina Goldkuhl contributed to the Swedish Lymphoma Registry and participated in the writing of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Ninja Övergaard https://orcid.org/0000-0001-9222-9619
Ingrid Glimelius https://orcid.org/0000-0001-6158-3041

REFERENCES
1. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–54.
2. Engert A, Haeverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.
3. Johnson P, Federico M, Kirkwood A, Fossa S, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–29.
4. Borchmann P, Goergen H, Kope C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790–802.
5. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71:222–32.
6. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR, et al. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119:432–40.
7. Evens AM, Hellenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–5.
8. Enblad G, Gilmelius B, Sundstrom C. Treatment outcome in Hodgkin’s disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2:297–302.
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.
10. Kolstad A, Nome O, Delabie J, Lauritzen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48:570–6.

11. Evens AM, Hong F, Gordon LJ, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161:76–86.

12. Ballova V, Rüffer JU, Havercamp H, Pfistner B, Müller-Hermelink HK, Dühmek E, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD16/97). Ann Oncol. 2005;16:124–31.

13. Boell B, Fosså S, Goergen H, Kamper P, Leppa S, Molin D, et al. B-Case (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Blood. 2018;132:926.

14. Terschüren C, Gierer S, Brillant C, Paulus U, Löfler M, Hoffmann W. Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol. 2010;21:2045–51.

15. Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood. 2012;119:990–6.

16. Glimelius I, Ekberg S, Jerkmann M, Chang ET, Björkholm M, Andersson TM, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009: trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90:1128–34.

17. Bjorkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW. Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden. Eur J Haematol. 2018;101:106–14.

18. Pulte D, Jansen L, Gondos A, Emrick K, Holleczek B, Kalatilnic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol. 2014;164:851–7.

19. Chatenoud L, Bertuccio P, Bosetti C, Rodriguez T, Levi F, Negri E, et al. Hodgkin’s lymphoma mortality in the Americas, 1997–2008: achievements and persistent inadequacies. Int J Cancer. 2013;133:687–94.

20. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111:2977–83.

21. Barlow L, Westergren K, Holmberg L, Talback M, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.

22. Swedish Lymphoma Registry. Swedish Lymphoma Registry. 2020. https://www.cancercentrum.se/samverkan/cancerdiagnoser/hodgkins-lymfom/vardprogram/. Accessed 14 September 2020.

23. Swedish Lymphoma Study Group. Swedish Lymphoma Study Group. 2020. http://www.swedishlymphoma.se/. Accessed 14 September 2020.

24. Starkweather CW. The epigenesis of stuttering. J Fluency Disord. 2002;27:269–87.

25. Swedish National Board of Health and Welfare. Causes of Death Registry. 2020. https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/dodsorsakregistret/. Accessed 14 September 2020.

26. Regionalt Cancercentrum i samverkan. Swedish national guidelines - Hodgkin lymphoma. 2020. https://kunskapsbanken.cancercentrum.se/diagnoser/hodgkins-lymfom/vardprogram/. Accessed 14 September 2020.

27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

28. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187–220.

29. Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76:1687–8.

30. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103–17.

31. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no 10, end results evaluation section. Bethesda, MD: National Cancer Institute; 1959.

32. Perme MP, Henderson R, Stare J. An approach to estimation in relative survival regression. Biostatistics. 2009;10:136–46.

33. Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119:6005–15.

34. Junlén HR, Petersson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29:668–76.

35. Molin D, Linderoth J, Wahlin BE. Nodal lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. Br J Haematol. 2017;177:449–56.

36. Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–92.

37. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418–27.

38. Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170:179–84.

39. Grib A, Pirrie SJ, Linton K, Warbye V, Paterson K, Davies AJ, et al. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br J Haematol. 2020;193:63–71.

40. Jalali A, Ha FJ, Chong G, Grigg A, Mickendrick J, Schwarer AP, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016;95:809–16.

41. Andjelic B, Antic D, Jakovic L, Todorovic M, Bogdanovic A, Djurasic-Novic V, et al. A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice. Eur J Haematol. 2014;93:392–9.

42. Federico M, Lumiani S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27:805–11.

43. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005;23:9208–18.

44. Carpe P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the
phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34:2028–36.

45. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles \( \geq 4 \) baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Ann Oncol. 2014;25:1622–8.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Wahlin BE, Övergaard N, Peterson S, et al. Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged > 60 years. eJHaem. 2021;1–13.

https://doi.org/10.1002/jha2.202